<DOC>
	<DOC>NCT01950481</DOC>
	<brief_summary>Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired hepatic function and healthy subjects with normal hepatic function.</brief_summary>
	<brief_title>Effect of Hepatic Impairment on LDK378 Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Inclusion Criteria (all groups): Male Subjects between 1870 years of age Female subjects between 1870 years of age who are postmenopausal or sterile Body Mass Index (BMI) of 18.0 36.0 kg/m2, with body weight â‰¥ 50 kg. Inclusion (group mild, moderate and severe hepatic impairment): Subjects with confirmed cirrhosis Exclusion Criteria (all groups): impaired cardiac function concurrent severe and/or uncontrolled medical conditions Exclusion Criteria (moderate, mild and severe groups): Clinical evidence of severe ascites Use of PPIs within 10 days prior to 2 days after LDK378 dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>LDK378</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>